Skye Bioscience, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SKYE research report →
About the company
Skye Bioscience, Inc. , a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation.
- CEO
- Punit Dhillon
- IPO
- 2015
- Employees
- 12
- HQ
- San Diego, CA, US
Price Chart
- Market Cap
- $24.62M
- P/E
- -0.49
- P/S
- 0.00
- P/B
- 3.08
- EV/EBITDA
- -0.30
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -217.27%
- ROIC
- -633.68%
- Revenue
- $0 · 0.00%
- Net Income
- $-55,924,814 · -110.50%
- EPS
- $-1.41 · -93.15%
- Op Income
- $-58,163,565
- FCF YoY
- -60.46%
- 52W High
- $4.99
- 52W Low
- $0.57
- 50D MA
- $0.79
- 200D MA
- $1.18
- Beta
- 2.94
- Avg Volume
- 182.03K
Get TickerSpark's AI analysis on SKYE
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 31, 26 | Sharp John P | other | 0 |
| Mar 31, 26 | Smith Karen L. | other | 75,000 |
| Mar 31, 26 | Twitty Christopher | other | 200,000 |
| Mar 31, 26 | Twitty Christopher | other | 150,000 |
| Mar 31, 26 | Twitty Christopher | other | 75,000 |
| Mar 31, 26 | Twitty Christopher | other | 17,004 |
| Mar 31, 26 | Twitty Christopher | other | 12,000 |
| Mar 31, 26 | Twitty Christopher | other | 7,100 |
| Mar 31, 26 | Twitty Christopher | sell | 200,000 |
| Mar 31, 26 | Twitty Christopher | sell | 7,100 |
Our SKYE coverage
Recent articles, reports, and earnings notes.
No research on SKYE yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SKYE report →Similar companies
Peers in the same neighborhood.